Wedbush Reaffirms “Outperform” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush’s price target points to a potential upside of 140.55% from the company’s previous close.

Several other equities research analysts have also weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Stock Down 3.3 %

TScan Therapeutics stock opened at $2.91 on Monday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69. The firm’s fifty day simple moving average is $4.51 and its 200-day simple moving average is $5.60. The company has a market capitalization of $155.31 million, a P/E ratio of -2.75 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new position in TScan Therapeutics in the 2nd quarter worth approximately $70,000. SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics in the third quarter worth $78,000. The Manufacturers Life Insurance Company bought a new position in TScan Therapeutics during the second quarter worth $90,000. XTX Topco Ltd acquired a new position in TScan Therapeutics during the 3rd quarter valued at $112,000. Finally, MetLife Investment Management LLC boosted its holdings in TScan Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after purchasing an additional 13,164 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.